BRNS
NASDAQ
$0.61
Barinthus Biotherapeutics Plc. (BRNS)
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company is headquartered in Harwell, the United Kingdom.
Sector:
Healthcare
Industry:
Biotechnology
Target: $5.50 (+807.44%)
Market Cap
$26M
P/B Ratio
0.38
Beta (5Y)
0.70
Price Chart
Valuation
Market Cap$26M
P/S3.80
P/B0.38
Profitability
Gross Profit (TTM)-$336K
EBITDA-$51M
Profit Margin-54.2%
Operating Margin-62.7%
EPS-$1.29
Growth & Risk
FCF 5Y CAGR+18.92%
Beta (5Y)0.70
Sharpe Ratio-0.64